Unity Biotechnology (NASDAQ:UBX – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.15, Yahoo Finance reports.
Unity Biotechnology Price Performance
UBX traded up $0.02 during trading on Wednesday, hitting $1.41. The company’s stock had a trading volume of 19,390 shares, compared to its average volume of 70,986. Unity Biotechnology has a twelve month low of $1.22 and a twelve month high of $2.67. The firm’s 50 day moving average price is $1.46 and its 200-day moving average price is $1.57. The stock has a market cap of $23.67 million, a PE ratio of -0.56 and a beta of 0.84.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Unity Biotechnology in a report on Wednesday, May 15th.
About Unity Biotechnology
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
Read More
- Five stocks we like better than Unity Biotechnology
- Best Stocks Under $10.00
- What Are Bonds? A High-Level Overview
- Stock Splits, Do They Really Impact Investors?
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
